Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1371550

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1371550

Antimalarial Drugs Market - Global Antimalarial Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4795

Add to Cart

Description

Table of Contents

Antimalarial Drugs Market Poised for Significant Growth, Reaching US$1.5 Billion by 2030.

The global antimalarial drugs market is on track for substantial growth, with projections indicating that it will reach a valuation of US$1.5 billion by 2030, up from US$1.1 billion in 2022. This promising trajectory is expected to be driven by a compound annual growth rate (CAGR) of 5.2% between 2023 and 2030, according to a recent market analysis.

Key Trends Fueling Market Growth

Several key trends are expected to fuel the growth of the global antimalarial drugs market. These trends include:

Increasing Malaria Prevalence: Malaria remains a global health concern, particularly in tropical and subtropical regions. The rise in reported cases and drug-resistant malaria strains has created a pressing need for effective antimalarial drugs. Pharmaceutical companies are investing in research and development to formulate new, more potent antimalarial drugs and improve existing treatments.

Multiple Pipeline Products: The presence of numerous pipeline products is driving market growth. Pharmaceutical companies are actively developing and testing various potential antimalarial treatments, including novel drug and vaccine candidates. This robust pipeline underscores the industry's commitment to addressing the ongoing malaria challenge.

Growing Healthcare Expenditure: Increasing global healthcare expenditure is another significant driver of the antimalarial drugs market. As countries allocate more resources to healthcare, there is a greater focus on combating diseases like malaria. This includes investments in research, development, and distribution of antimalarial drugs.

Challenges and Opportunities

Despite the positive outlook, the market faces challenges such as poor demand in underdeveloped countries, limited healthcare access, awareness issues, and affordability constraints. Addressing these challenges will be crucial for promoting antimalarial drug usage in underdeveloped regions.

Another challenge is the proliferation of counterfeit antimalarial drugs, which poses a significant threat to patient safety and erodes trust in genuine products. Robust quality control measures and regulatory enforcement are essential to combat this issue effectively.

On the opportunities front, the adoption of pharmacogenomics, nanotechnology, and point-of-care diagnostics offers promising avenues for improving antimalarial drug treatments. Pharmacogenomics allows for personalized treatments based on an individual's genetic profile, minimizing adverse reactions and enhancing treatment outcomes.

Nanotechnology leverages nanoparticles and nanoscale drug delivery systems to improve drug solubility, stability, and targeted delivery to malaria parasites. This innovation has the potential to revolutionize antimalarial drug development.

Additionally, point-of-care diagnostics provide rapid and accurate malaria diagnosis in remote or resource-limited settings, enabling timely treatment and reducing the risk of complications.

Key Segments and Market Leaders

Aminoquinolines Drug Class: Aminoquinolines, such as chloroquine and hydroxychloroquine, historically captured the largest market share due to their effectiveness against various malaria strains, low cost, and extensive availability.

Oral Route of Administration: The oral route of administration has captured the largest market share due to its convenience, ease of patient compliance, and suitability for self-administration.

Hospital Pharmacies: Hospital pharmacies have a dominant market share, particularly in managing severe and complicated malaria cases.

Asia Pacific: Asia Pacific dominates the market for antimalarial drugs due to high malaria incidence, significant investments in healthcare facilities, and a sizable population.

Europe's Notable Performance

Europe is anticipated to exhibit the highest CAGR in the antimalarial drugs market, driven by factors such as rising travelers to malaria-endemic regions, increasing immigration from such areas, and the potential for malaria re-emergence in some European countries.

Market Leaders

Several key players are leading the global antimalarial drugs market. These include Pfizer Inc., Novartis AG, Roche Holding AG, Alvizia Healthcare Pvt. Ltd., Merck & Co, Sanofi SA, GlaxoSmithKline Plc, Sun Pharmaceutical Industries Ltd., Viatris, Guilin Pharmaceutical Co., Ltd., Ajanta Pharma Limited, AbbVie Inc, Bayer AG, Cipla Limited, and Ipca Laboratories Ltd.

Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Antimalarial Drugs Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Antimalarial Drugs Market Outlook, 2018 - 2030

  • 3.1. Global Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Aminoquinolines
      • 3.1.1.2. Quinoline-methanol (4-quinolinemethanols)
      • 3.1.1.3. Cinchona Alkaloids
      • 3.1.1.4. Biguanides
      • 3.1.1.5. Sulfonamides and Sulfones
      • 3.1.1.6. Artemisinin Derivatives
      • 3.1.1.7. Others
  • 3.2. Global Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Injectable
  • 3.3. Global Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Retail Pharmacies
      • 3.3.1.3. Online Pharmacies
      • 3.3.1.4. Other
  • 3.4. Global Antimalarial Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Antimalarial Drugs Market Outlook, 2018 - 2030

  • 4.1. North America Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Aminoquinolines
      • 4.1.1.2. Quinoline-methanol (4-quinolinemethanols)
      • 4.1.1.3. Cinchona Alkaloids
      • 4.1.1.4. Biguanides
      • 4.1.1.5. Sulfonamides and Sulfones
      • 4.1.1.6. Artemisinin Derivatives
      • 4.1.1.7. Others
  • 4.2. North America Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Injectable
  • 4.3. North America Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Retail Pharmacies
      • 4.3.1.3. Online Pharmacies
      • 4.3.1.4. Other
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 4.4.1.2. U.S. Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.4.1.3. U.S. Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.4.1.4. U.S. Antimalarial Drugs Market End Use, Value (US$ Bn), 2018 - 2030
      • 4.4.1.5. Canada Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 4.4.1.6. Canada Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.4.1.7. Canada Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.4.1.8. Canada Antimalarial Drugs Market End Use, Value (US$ Bn), 2018 - 2030
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Antimalarial Drugs Market Outlook, 2018 - 2030

  • 5.1. Europe Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Aminoquinolines
      • 5.1.1.2. Quinoline-methanol (4-quinolinemethanols)
      • 5.1.1.3. Cinchona Alkaloids
      • 5.1.1.4. Biguanides
      • 5.1.1.5. Sulfonamides and Sulfones
      • 5.1.1.6. Artemisinin Derivatives
      • 5.1.1.7. Others
  • 5.2. Europe Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Injectable
  • 5.3. Europe Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Retail Pharmacies
      • 5.3.1.3. Online Pharmacies
      • 5.3.1.4. Other
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.2. Germany Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.3. Germany Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.4. U.K. Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.5. U.K. Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.6. U.K. Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.7. France Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.8. France Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.9. France Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.10. Italy Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.11. Italy Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.12. Italy Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.13. Turkey Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.14. Turkey Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.15. Turkey Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.16. Russia Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.17. Russia Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.18. Russia Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.19. Rest of Europe Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 5.4.1.20. Rest of Europe Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.4.1.21. Rest of Europe Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antimalarial Drugs Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Aminoquinolines
      • 6.1.1.2. Quinoline-methanol (4-quinolinemethanols)
      • 6.1.1.3. Cinchona Alkaloids
      • 6.1.1.4. Biguanides
      • 6.1.1.5. Sulfonamides and Sulfones
      • 6.1.1.6. Artemisinin Derivatives
      • 6.1.1.7. Others
  • 6.2. Asia Pacific Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Injectable
  • 6.3. Asia Pacific Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Retail Pharmacies
      • 6.3.1.3. Online Pharmacies
      • 6.3.1.4. Other
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 6.4.1.2. China Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.4.1.3. China Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.4. Japan Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 6.4.1.5. Japan Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.4.1.6. Japan Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.7. South Korea Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 6.4.1.8. South Korea Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.4.1.9. South Korea Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.10. India Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 6.4.1.11. India Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.4.1.12. India Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.13. Southeast Asia Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 6.4.1.14. Southeast Asia Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.4.1.15. Southeast Asia Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.16. Rest of Asia Pacific Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 6.4.1.17. Rest of Asia Pacific Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.4.1.18. Rest of Asia Pacific Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antimalarial Drugs Market Outlook, 2018 - 2030

  • 7.1. Latin America Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Aminoquinolines
      • 7.1.1.2. Quinoline-methanol (4-quinolinemethanols)
      • 7.1.1.3. Cinchona Alkaloids
      • 7.1.1.4. Biguanides
      • 7.1.1.5. Sulfonamides and Sulfones
      • 7.1.1.6. Artemisinin Derivatives
      • 7.1.1.7. Others
  • 7.2. Latin America Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Injectable
  • 7.3. Latin America Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Retail Pharmacies
      • 7.3.1.3. Online Pharmacies
      • 7.3.1.4. Other
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 7.4.1.2. Brazil Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.4.1.3. Brazil Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.4. Mexico Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 7.4.1.5. Mexico Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.4.1.6. Mexico Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.7. Argentina Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 7.4.1.8. Argentina Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.4.1.9. Argentina Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.10. Rest of Latin America Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 7.4.1.11. Rest of Latin America Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.4.1.12. Rest of Latin America Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antimalarial Drugs Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Antimalarial Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Aminoquinolines
      • 8.1.1.2. Quinoline-methanol (4-quinolinemethanols)
      • 8.1.1.3. Cinchona Alkaloids
      • 8.1.1.4. Biguanides
      • 8.1.1.5. Sulfonamides and Sulfones
      • 8.1.1.6. Artemisinin Derivatives
      • 8.1.1.7. Others
  • 8.2. Middle East & Africa Antimalarial Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Injectable
  • 8.3. Middle East & Africa Antimalarial Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Retail Pharmacies
      • 8.3.1.3. Online Pharmacies
      • 8.3.1.4. Other
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Antimalarial Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 8.4.1.2. GCC Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.4.1.3. GCC Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.4. South Africa Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 8.4.1.5. South Africa Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.4.1.6. South Africa Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.7. Egypt Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 8.4.1.8. Egypt Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.4.1.9. Egypt Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.10. Nigeria Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 8.4.1.11. Nigeria Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.4.1.12. Nigeria Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.13. Rest of Middle East & Africa Antimalarial Drugs Market by Drug Class, Value (US$ Bn), 2018 - 2030
      • 8.4.1.14. Rest of Middle East & Africa Antimalarial Drugs Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.4.1.15. Rest of Middle East & Africa Antimalarial Drugs Market Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs Drug Class Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Novartis AG
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Roche Holding AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Johnson & Johnson
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Merck & Co., Inc
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Sanofi S.A.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. GlaxoSmithKline plc
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. AstraZeneca plc
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Eli Lilly and Company
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Gilead Sciences, Inc.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. AbbVie Inc
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Bayer AG
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. Biogen Inc.
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Product Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Moderna, Inc.
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Product Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!